Coherus Biosciences | CHRS - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 362.52M 357.69M 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amarin USD 3K 5K 2024-12
Amgen USD 657M 4M 2026-03
Baxter International USD 58M 14M 2025-09
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 411M 21M 2026-03
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Fujifilm JPY 863M 429M 2026-03
Gilead Sciences USD 240M 15M 2026-03
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Merck USD 479M 67M 2026-03
Myriad Genetics USD 4.4M 600K 2025-12
Pacira USD 3.7M 193K 2026-03
Perrigo USD 7.98B 7.94B 2026-03
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 4.7M 2.65M 2026-03
Zoetis USD 62M 5M 2026-03